Sanofi

In News

Sanofi Multiple Sclerosis Drug Hit by Double Setback - The Wall Street Journal

The Wall Street Journal - Dec 15, 2025

Sanofi flags delay in FDA's decision on tolebrutinib, shares fall - Reuters

Reuters - Dec 15, 2025

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis - GlobeNewswire

GlobeNewswire - Dec 15, 2025

Sanofi’s MS Drug Takes Double Hit With FDA Delay, Trial Failure - Bloomberg.com

Bloomberg.com - Dec 15, 2025

Sanofi’s tolebrutinib fails primary endpoint in multiple sclerosis trial - Investing.com

Investing.com - Dec 15, 2025

InduPro Therapeutics Secures Sanofi Strategic Equity Investment - Pulse 2.0

Pulse 2.0 - Dec 15, 2025

Sanofi’s tolebrutinib flunks primary MS pivotal trial, FDA verdict on secondary disease further delayed - FirstWord Pharma

FirstWord Pharma - Dec 14, 2025

Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies - Fierce Biotech

Fierce Biotech - Dec 10, 2025

Sanofi: Regulatory Decision For Tolebrutinib To Be Delayed - Nasdaq

Nasdaq - Dec 15, 2025

Sanofi’s tolebrutinib falls short in phase 3 PERSEUS trial for primary progressive multiple sclerosis - Seeking Alpha

Seeking Alpha - Dec 15, 2025

Sanofi Says FDA Decision On Tolebrutinib Expected To Be Delayed - TradingView — Track All Markets

TradingView — Track All Markets - Dec 15, 2025

Sanofi (SNY) Halts Regulatory Plans for Tolebrutinib in PPMS - GuruFocus

GuruFocus - Dec 15, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment